NCT03922035View on ClinicalTrials.gov

CBM588 in Improving Clinical Outcomes in Patients Who Have Undergone Donor Hematopoietic Stem Cell Transplant

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

April 18, 2019

Primary Completion Date

March 4, 2026

Study Completion Date

March 4, 2026

Conditions
Hematopoietic and Lymphoid Cell Neoplasm
Interventions
OTHER

Best Practice

Receive standard peri-/post-transplant supportive care

DRUG

Clostridium butyricum CBM 588 Probiotic Strain

Given PO

Trial Locations (1)

91010

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER